Cancer Drug Spending Doubled In Past 5 Years, Expected To Redouble In Next 5 Years

Spending on cancer drugs doubled in the past five years and is expected to double again in the next five years, but employers paid most of the increased costs. The average cancer patient with commercial insurance paid less than $500 per year for outpatient non-retail medicines in 2017, and even those patient costs were often reduced by drug company coupons according to a IQVIA Institute for Human Data Science Study. The median annual launch price of cancer drugs in 2017...